Literature DB >> 12122115

1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system.

Yan Chun Li1, Juan Kong, Minjie Wei, Zhou-Feng Chen, Shu Q Liu, Li-Ping Cao.   

Abstract

Inappropriate activation of the renin-angiotensin system, which plays a central role in the regulation of blood pressure, electrolyte, and volume homeostasis, may represent a major risk factor for hypertension, heart attack, and stroke. Mounting evidence from clinical studies has demonstrated an inverse relationship between circulating vitamin D levels and the blood pressure and/or plasma renin activity, but the mechanism is not understood. We show here that renin expression and plasma angiotensin II production were increased severalfold in vitamin D receptor-null (VDR-null) mice, leading to hypertension, cardiac hypertrophy, and increased water intake. However, the salt- and volume-sensing mechanisms that control renin synthesis are still intact in the mutant mice. In wild-type mice, inhibition of 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] synthesis also led to an increase in renin expression, whereas 1,25(OH)(2)D(3) injection led to renin suppression. We found that vitamin D regulation of renin expression was independent of calcium metabolism and that 1,25(OH)(2)D(3) markedly suppressed renin transcription by a VDR-mediated mechanism in cell cultures. Hence, 1,25(OH)(2)D(3) is a novel negative endocrine regulator of the renin-angiotensin system. Its apparent critical role in electrolytes, volume, and blood pressure homeostasis suggests that vitamin D analogues could help prevent or ameliorate hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122115      PMCID: PMC151055          DOI: 10.1172/JCI15219

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  LXRalpha functions as a cAMP-responsive transcriptional regulator of gene expression.

Authors:  K Tamura; Y E Chen; M Horiuchi; Q Chen; L Daviet; Z Yang; M Lopez-Ilasaca; H Mu; R E Pratt; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  VDR-Alien: a novel, DNA-selective vitamin D(3) receptor-corepressor partnership.

Authors:  P Polly; M Herdick; U Moehren; A Baniahmad; T Heinzel; C Carlberg
Journal:  FASEB J       Date:  2000-07       Impact factor: 5.191

3.  Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction.

Authors:  D K Panda; D Miao; M L Tremblay; J Sirois; R Farookhi; G N Hendy; D Goltzman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  Retinoic acid-mediated activation of the mouse renin enhancer.

Authors:  Q Shi; K W Gross; C D Sigmund
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

5.  Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women.

Authors:  M Pfeifer; B Begerow; H W Minne; D Nachtigall; C Hansen
Journal:  J Clin Endocrinol Metab       Date:  2001-04       Impact factor: 5.958

6.  Effectiveness of 1,25-dihydroxyvitamin D supplementation on blood pressure reduction in a pseudohypoparathyroidism patient with high renin activity.

Authors:  Y Kimura; M Kawamura; M Owada; T Oshima; M Murooka; T Fujiwara; K Hiramori
Journal:  Intern Med       Date:  1999-01       Impact factor: 1.271

7.  Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism.

Authors:  Y C Li; M J Bolt; L P Cao; M D Sitrin
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-09       Impact factor: 4.310

8.  Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition.

Authors:  H F Cheng; J L Wang; M Z Zhang; S W Wang; J A McKanna; R C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2001-03

9.  Genetic ablation of parathyroid glands reveals another source of parathyroid hormone.

Authors:  T Günther; Z F Chen; J Kim; M Priemel; J M Rueger; M Amling; J M Moseley; T J Martin; D J Anderson; G Karsenty
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

10.  Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.

Authors:  A A Geisterfer; M J Peach; G K Owens
Journal:  Circ Res       Date:  1988-04       Impact factor: 17.367

View more
  657 in total

1.  Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative.

Authors:  Macarius M Donneyong; Carlton A Hornung; Kira C Taylor; Richard N Baumgartner; John A Myers; Charles B Eaton; Eiran Z Gorodeski; Liviu Klein; Lisa W Martin; James M Shikany; Yiqing Song; Wenjun Li; JoAnn E Manson
Journal:  Circ Heart Fail       Date:  2014-11-14       Impact factor: 8.790

Review 2.  Can vitamin D slow down the progression of chronic kidney disease?

Authors:  Rukshana Shroff; Mandy Wan; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2011-12-10       Impact factor: 3.714

Review 3.  Vitamin D: roles in renal and cardiovascular protection.

Authors:  Yan C Li
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

Review 4.  Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.

Authors:  Raimund H Pichler; Ian H de Boer
Journal:  Curr Diab Rep       Date:  2010-08       Impact factor: 4.810

Review 5.  The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes.

Authors:  Anand Vaidya; Jonathan S Williams
Journal:  Metabolism       Date:  2011-11-09       Impact factor: 8.694

Review 6.  The role of vitamin D in the FGF23, klotho, and phosphate bone-kidney endocrine axis.

Authors:  Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Ryan Forster; Rimpi Saini; Jui-Cheng Hsieh; Carol A Haussler; Peter W Jurutka
Journal:  Rev Endocr Metab Disord       Date:  2012-03       Impact factor: 6.514

7.  Association between serum 25-hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism.

Authors:  Marcella D Walker; Elaine Cong; Anna Kepley; Marco R Di Tullio; Tatjana Rundek; Shunichi Homma; James A Lee; Rui Liu; Polly Young; Chiyuan Zhang; Donald J McMahon; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2013-11-27       Impact factor: 5.958

8.  Effects of vitamin D(2) supplementation on insulin sensitivity and metabolic parameters in metabolic syndrome patients.

Authors:  S Wongwiwatthananukit; N Sansanayudh; N Phetkrajaysang; S Krittiyanunt
Journal:  J Endocrinol Invest       Date:  2013-02-04       Impact factor: 4.256

9.  Vitamin D is a regulator of endothelial nitric oxide synthase and arterial stiffness in mice.

Authors:  Olena Andrukhova; Svetlana Slavic; Ute Zeitz; Sabine C Riesen; Monika S Heppelmann; Tamas D Ambrisko; Mato Markovic; Wolfgang M Kuebler; Reinhold G Erben
Journal:  Mol Endocrinol       Date:  2013-01-01

10.  Effects of vitamin D supplementation on cardiometabolic outcomes in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Hanne Hauger; Rikke Pilmann Laursen; Christian Ritz; Christian Mølgaard; Mads Vendelbo Lind; Camilla Trab Damsgaard
Journal:  Eur J Nutr       Date:  2020-02-14       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.